Hims & Hers Health, Inc. is under investigation after the FTC sued the company for allegedly sharing customers' medical information with third-party advertisers like Snap and Meta Platforms. The lawsuit accuses Hims & Hers of deceptive and unlawful privacy practices, leading to a significant stock price drop of over 14%. Investors who suffered losses from Hims & Hers securities may have legal rights and are encouraged to contact Kessler Topaz Meltzer & Check, LLP for potential securities litigation.
Hims & Hers Health reported disappointing Q3 results with subscriber numbers falling quarter-over-quarter and gross margin hitting a new low. The company also gave a weak outlook for Q4 and fiscal year 2026. However, much of this underperformance was...
The global telehealth market, valued at $77.4 billion in 2025, is projected to expand to $187.5 billion by 2033, driven by increasing patient demand for virtual care and advances in AI, remote monitoring, and wearable health devices. Companies like R...
Hims & Hers Health reported Q3 2026 revenue of $890.3 million, slightly missing analyst consensus by $2.5 million but meeting midpoint guidance. The company strategically reduced marketing spend to 28% of revenue, down from 39% the previous year, in ...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
